The automated suturing devices market is quietly becoming one of the more closely watched corners of the surgical device industry, according to DelveInsight's automated suturing devices research report - forecast till 2030. Sitting at USD 2.53 billion in 2023, the space is expected to climb at a CAGR of 6.81% over the coming years, reaching close to USD 3.74 billion by 2030 — a pace shaped by shifting surgical volumes, an aging patient base, and growing clinical confidence in mechanized closure tools.
At a practical level, an automatic suture device exists to solve a very old problem: manual suturing is slow, operator-dependent, and prone to variability. Automating that step brings more predictability to cardiovascular, gynecological, gastrointestinal, and orthopedic procedures alike, which is precisely why interest in the automated suturing device category has continued to build among hospitals and surgical centers looking to tighten procedure times.
What's Fueling the Climb
Cancer remains the single biggest force behind rising surgical volume. Per WHO 2022 estimates, breast cancer alone accounted for 2.26 million new cases in 2020, with lung, colorectal, and prostate cancers close behind. More diagnoses inevitably mean more operating-room time, and that steady drumbeat of procedures continues to underpin the us wound closure devices market in particular.
Injury and trauma statistics add another layer. WHO reporting suggests 20 to 50 million people globally experience non-fatal injuries each year, many leaving lasting impairment, while the International Labour Organization counts roughly 340 million workplace accidents annually. These numbers rarely make headlines, but they quietly sustain baseline demand across the wider automated suturing devices landscape year after year.
Regulators, for their part, have been active. Endo Tools Therapeutics won FDA approval for its Endomina system in January 2022, opening the door to endoscopic suturing within the gastrointestinal tract, while Anchora Medical's Su2ura Approximation Device cleared 510(k) review in mid-2021 for laparoscopic soft-tissue work. Approvals like these are steadily pushing the boundaries of what the endoluminal suturing devices market can address.
Not Without Obstacles
That said, the path forward isn't entirely smooth. A limited pool of surgeons trained on automated platforms, inconsistent device availability in certain geographies, and pricing that still outpaces conventional sutures all act as brakes on faster adoption. The pandemic-era pause in elective surgery also left a temporary dip in demand, one the market has largely worked through since.
Where the Growth Concentrates
Gynecological procedures deserve particular attention. WHO data points to about 604,000 new cervical cancer cases worldwide in 2020, alongside hundreds of thousands of additional ovarian and endometrial cancer diagnoses. That procedural load flows directly into the gynecology suture market, making it one of the more resilient application segments through the forecast period.
North America, meanwhile, looks set to hold its position at the top. The WHO recorded more than 13 million U.S. surgical procedures between January 2019 and January 2021, and nearly 55.4 million motor-vehicle injuries occurred in the country in 2020 alone. With the CDC noting that six in ten American adults live with at least one chronic condition, the us automated suturing devices market is well positioned to keep leading on a global basis.
Companies active in this space include Medtronic, LSI Solutions, Sutrue Limited, Apollo Endosurgery, B. Braun Melsungen AG, Becton, Dickinson & Company, Ethicon (Johnson & Johnson), Smith & Nephew, EndoEvolution, Mellon Medical B.V., Endo Tools Therapeutics, EDGe Surgical, Medical Microinstruments, and SuturTek, among others.
The Road Ahead
With clearer regulatory pathways and broader clinical acceptance, the outlook through 2030 leans favorable. Those tracking the wider ecosystem may also want to look at DelveInsight's coverage of the suture anchor device market, the cardiac sutures market, and the united states surgical sutures market, all of which sit closely alongside this space.
Latest Reports Offered by Delveinsight
adrenoleukodystrophy market | alopecia aerata market | anterior cruciate ligament injuries market | anti-gbm market | arteriotomy closure devices market | arthroscopy devices market | ascites market | aspergillosis market | asthma diagnostic device market | audiology devices market | autonomic dysfunction market | basal cell carcinoma market | bladder cancer market | braf-mutant metastatic melanoma market | car t cell therapy for multiple myeloma market | cardiovascular calcification market | carpal tunnel syndrome market | cdk4/6 inhibitor market | central retinal vein occlusion market | chagas disease market | charcot marie tooth disease market | chronic heart failure market | chronic non-healing wounds market | chronic periodontitis market | chronic renal failure market | chronic thromboembolic pulmonary hypertension | cns lymphoma market | cone rod dystrophy market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk